Vericel to submit biologics license application to FDA: 4 observations

Vericel plans to submit a biologics license application to the FDA by the end of 2015 for MACI, a new biologic.

Advertisement

Here are four observations:

 

1. MACI is intended for the treatment of focal chondral cartilage defects in the knee.

 

2. MACI — matrix-applied characterized autologous cultured chondrocytes — is a third-generation autologous chondrocyte implantation product.

 

3. MACI was the first tissue-engineered product approved under the advanced therapy medicinal product guidelines by the European Commission.

 

4. Vericel is a developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions.

 

More articles on devices:
Blue Belt Technologies’s STRIDE knee system used in 1k procedures — 5 quick facts
Integra LifeSciences, Smith & Newphew, NuVasive & more — 14 key notes
Smith & Nephew voluntarily removes BIRMINGHAM HIP Resurfacing System components: 5 things to know

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.